AquaBounty Technologies Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AquaBounty Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AquaBounty Technologies stock.
View analyst ratings for AquaBounty Technologies or view top-rated stocks.

Wall Street analysts have given AquaBounty Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AquaBounty Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

AquaBounty Technologies saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,580,000 shares, an increase of 46.3% from the January 28th total of 1,080,000 shares. Based on an average daily trading volume, of 4,640,000 shares, the days-to-cover ratio is presently 0.3 days.
View AquaBounty Technologies' Short Interest.

AquaBounty Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for AquaBounty Technologies.

AquaBounty Technologies, Inc. (NASDAQ:AQB) announced its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The firm earned $0.07 million during the quarter, compared to analyst estimates of $1.79 million. AquaBounty Technologies had a negative net margin of 11,050.81% and a negative trailing twelve-month return on equity of 36.77%.
View AquaBounty Technologies' earnings history.

AquaBounty Technologies' stock was trading at $1.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AQB shares have increased by 271.9% and is now trading at $6.88.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12 month price targets for AquaBounty Technologies' shares. Their forecasts range from $3.50 to $9.00. On average, they anticipate AquaBounty Technologies' stock price to reach $5.83 in the next twelve months. This suggests that the stock has a possible downside of 15.2%.
View analysts' price targets for AquaBounty Technologies or view top-rated stocks among Wall Street analysts.

Some companies that are related to AquaBounty Technologies include BioCryst Pharmaceuticals (BCRX), Pulmonx (LUNG), bluebird bio (BLUE), Stoke Therapeutics (STOK), Bavarian Nordic A/S (BVNRY), Harmony Biosciences (HRMY), Kura Oncology (KURA), Silk Road Medical (SILK), UDG Healthcare (UDG), ModivCare (MODV), NGM Biopharmaceuticals (NGM), Inovio Pharmaceuticals (INO), ADC Therapeutics (ADCT), Aurinia Pharmaceuticals (AUPH) and C4 Therapeutics (CCCC).
View all of AQB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AquaBounty Technologies investors own include Celldex Therapeutics (CLDX), Precigen (PGEN), ZIOPHARM Oncology (ZIOP), AbbVie (ABBV), Ocular Therapeutix (OCUL), AT&T (T), Aurora Cannabis (ACB), Allena Pharmaceuticals (ALNA), Evofem Biosciences (EVFM) and Rigel Pharmaceuticals (RIGL).

AquaBounty Technologies trades on the NASDAQ under the ticker symbol "AQB."

AquaBounty Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Third Security LLC (25.86%), Epiq Partners LLC (1.46%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), Nikko Asset Management Americas Inc. (0.28%), Capital Impact Advisors LLC (0.27%) and Voloridge Investment Management LLC (0.10%). Company insiders that own AquaBounty Technologies stock include David A Frank, Randal J Kirk, Richard L Huber and Rick L Sterling.
View institutional ownership trends for AquaBounty Technologies.

AQB stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Epiq Partners LLC, Third Security LLC, Winthrop Advisory Group LLC, Cambridge Investment Research Advisors Inc., and KBC Group NV.
View insider buying and selling activity for AquaBounty Technologies or view top insider-selling stocks.

AQB stock was acquired by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC, Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, Citigroup Inc., Bank of New York Mellon Corp, Exencial Wealth Advisors LLC, Wells Fargo & Company MN, and Nikko Asset Management Americas Inc.. Company insiders that have bought AquaBounty Technologies stock in the last two years include David A Frank, Randal J Kirk, Richard L Huber, and Rick L Sterling.
View insider buying and selling activity for AquaBounty Technologies or or view top insider-buying stocks.

Shares of AQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AQB stock can currently be purchased for approximately $6.88.

AquaBounty Technologies has a market capitalization of $484.68 million and generates $190,000.00 in revenue each year. The company earns $-13,230,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

AquaBounty Technologies employs 71 workers across the globe.

The official website for AquaBounty Technologies is www.aquabounty.com.

AquaBounty Technologies is headquartered at 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754.

AquaBounty Technologies' mailing address is 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754. The company can be reached via phone at 978-648-6000 or via email at [email protected]